Today we’re going to bring you an inside look into an Italian pharmaceutical firm with over 135 years of history. 

Founded in 1886 in Naples under the name of Farmacia Internazionale, our guest for today is from Menarini Group, a leading pharmaceutical and diagnostics company with a presence in over 140 countries. 

The firm prides itself as a leading provider of important healthcare brands, with its 18 manufacturing plants producing over 609 million packets of products a year. 

To this end, Menarini said it operates across the entire commercial value chain, from clinical development, regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields. 

That includes Consumer Health, Dermatology, Allergy or Respiratory, Gastroenterology, Cardio-metabolic, Anti-infectives, Oncology or Specialty Care and more.

All in, Menarini reported consolidated turnover of 4.375 billion euros in 2023, with international markets contributing 79% to the numbers. But how much of this is contributed by demand from the Asia-Pacific region? 

Meanwhile, Menarini is also seeing a number of interesting developments of late. For one thing, Menarini APAC had in June 2024 expanded its partnership with Pharmacosmos to tackle iron deficiency in patients in Singapore and Malaysia. 

So just how important are such licensing deals and partnerships in helping Menarini broaden its offerings while lowering R&D costs?

On Under the Radar, Money Matters’ finance presenter Chua Tian Tian posed these questions to Glen Godresse, CEO, Menarini APAC.

Today we&rsquo;re going to bring you an inside look into an Italian pharmaceutical firm with over 135 years of history.&nbsp;
Founded in 1886 in Naples under the name of Farmacia Internazionale, our guest for today is from Menarini Group, a leading pharmaceutical and diagnostics company with a presence in over 140 countries.&nbsp;
The firm prides itself as a leading provider of important healthcare brands, with its 18 manufacturing plants producing over 609 million packets of products a year.&nbsp;
To this end, Menarini said it operates across the entire commercial value chain, from clinical development, regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields.&nbsp;
That includes Consumer Health, Dermatology, Allergy or Respiratory, Gastroenterology, Cardio-metabolic, Anti-infectives, Oncology or Specialty Care and more.
All in, Menarini reported consolidated turnover of 4.375 billion euros in 2023, with international markets contributing 79% to the numbers. But how much of this is contributed by demand from the Asia-Pacific region?&nbsp;
Meanwhile, Menarini is also seeing a number of interesting developments of late. For one thing, Menarini APAC had in June 2024 expanded its partnership with Pharmacosmos to tackle iron deficiency in patients in Singapore and Malaysia.&nbsp;
So just how important are such licensing deals and partnerships in helping Menarini broaden its offerings while lowering R&amp;D costs?
On Under the Radar, Money Matters&rsquo; finance presenter Chua Tian Tian posed these questions to Glen Godresse, CEO, Menarini APAC.

We speak with businesses, industry leaders, venture capitalists and startups on their assessment of the business environment they're in, and what the future holds for them.

We speak with businesses, industry leaders, venture capitalists and startups on their assessment of the business environment they're in, and what the future holds for them.

Under The Radar

Under the Radar: What should we know about Italian pharmaceutical giant Menarini’s growth story in APAC and how important are partnerships to the firm?